GlaxoSmithKline (GSK) has announced it is to invest £275 million in three of its manufacturing sites in the UK.
The investment, which comes despite the recent Brexit vote, will help boost the production of the group’s medical facilities at Barnard Castle, Co. Durham; Montrose, Scotland; and Ware, Hertfordshire.
In a statement, GSK said that it views the UK as an attractive location for ‘investment in advanced manufacturing due to a number of factors including the skilled workforce, technological and scientific capabilities and infrastructure and a competitive corporate tax system’.
‘Today’s announcement reflects further investment to support our pharmaceutical pipeline and meet growing demand for our innovative portfolio of newly launched products,” said GSK chief executive Andrew Witty. “It is testament to our skilled UK workforce and the country’s leading position in life sciences that we are making these investments in advanced manufacturing here.”
© 2016 European Supermarket Magazine – your source for the latest retail news. Article by Stephen Wynne-Jones. To subscribe to ESM: The European Supermarket Magazine, click here.
